IntegraGen announced a collaboration with investigators from the New EPOC study to validate the oncology biomarker hsamiR313p.
hsamiR313p a microRNA whose expression has been shown to be a predictor of progression free survival in patients with metastatic colorectal cancer treated with anti‐EGFR therapy. The New EPOC study is a randomized clinical trial of chemotherapy alone compared to chemotherapy in combination with cetuximab, an anti‐EGFR antibody, in 272 KRAS wild‐type patients with operable metastases from colorectal cancer.
The present collaboration will explore the expression levels of hsamiR313p in both primary and metastatic tumors and determine the ability of the biomarker to predict patient outcomes.
A previously conducted study (link) has reported that hsamir313p expression in primary tumor samples was associated with anti‐EGFR response in KRAS wild‐type patients with mCRC receiving EGFR inhibitor therapy.
Related report: Biomarker Partnering Terms and Agreements
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View:Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View:Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity